Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment

International Ophthalmology

Volumn 24, Issue 3, 2001, Pages 151-159

  Hoerauf, Hans ^a   Klüter, Harald ^b   Joachimmeyer, Elke ^a   Roider, Johann ^a   Framme, Carsten ^a   Schlenke, Peter ^b   Kirchner, Holger ^a   Lagua, Horst ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF MANNHEIM   (Germany)

Author keywords

Autologous platelet concentrate; Autologous whole bl; ood; Inner limiting membrane; Macular hole; Vitrectomy

Indexed keywords

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD AUTOTRANSFUSION; CENTRAL RETINA ARTERY OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ENDOPHTHALMITIS; EPIRETINAL MEMBRANE; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; INJECTION; MALE; PERIMETRY; RETINA DETACHMENT; RETINA INJURY; RETINA MACULA EDEMA; RETINA MACULA HOLE; SCOTOMA; SECONDARY GLAUCOMA; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; VEIN OCCLUSION; VITRECTOMY; VITREOUS DISEASE;

ADULT; AGED; BLOOD; BLOOD PLATELETS; FEMALE; FLUOROCARBONS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETINAL PERFORATIONS; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 0036450908     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021566806836     Document Type: Article

References (35)

1. Freeman WR, Azen SP, Kim JW, El-Haig W, Mischell DR, Bailey I. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Arch Ophthalmol 1997; 115: 11-21.
2. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes: Results of a pilot study. Arch Ophthalmol 1991; 109: 654-659.
3. Kim WJ, Freeman WR, Azen SP, El-Haig W, Klein DJ, Bailey IL, and The Vitrectomy for Macular Hole Study Group. Prospective randomized trial of vitrectomy or observation for stage 2 macular holes. Am J Ophthalmol 1996; 121: 605-614.
4. Ruby AJ, Williams DF, Grand MG, Thomas MA, Meredith TA, Boniuk I. Pars plana vitrectomy for treatment of stage 2 macular holes. Arch Ophthalmol 1994; 112: 359-364.
5. Gaudric A, Massin P, Paques M, Santiago PY, Guez JE, Le Gargasson JF, Mundler O, Drouet L. Autologous platelet concentrate for the treatment of full thickness macular holes. Graefe's Arch Clin Exp Ophthalmol 1995; 233: 549-554.
6. Korobelnik JF, Hannouche D, Belayachi N, Branger M, Guez JE, Hoang-Xuan T. Autologous platelet concentrate as an adjunct in macular hole healing. Ophthalmology 103; 590-594.
7. Vine AK, Johnson MW. Thrombin in the management of full thickness macular holes. Retina 1996; 16: 474-478.
8. Liggett PE, Skolik SA, Horio B. Human autologous serum for the treatment of full thickness macular holes: A preliminary study. Ophthalmology 1995; 102: 1071-1076.
9. Rubin JS, Glaser BM, Thompson JT, Sjaarda RN, Pappas SS, Murphy RP. Vitrectomy, fluid-gas exchange and transforming growth factor-beta 2 for the treatment of traumatic macular holes. Ophthalmology 1995; 102: 1840-1845.
10. Smiddy WE, Glaser BM, Thompson JD, Sjaarda RN, Flynn HW, Hanham A, Murphy RP. Transforming growth factor-β2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Retina 1993; 13: 296-301.
11. Thompson JT, Smiddy WE, Williams GA. Comparison of recombinant TGF-β2 and placebo as an adjunctive agent for macular hole surgery. Ophthalmology 1995; 102(Suppl): 91.
12. Tilanus MAD, Deutman AF. Full thickness macular holes treated with vitrectomy and tissue glue. Int Ophthalmol 1995; 18: 355-358.
13. Eckardt C, Eckardt U. Entfernung der Membrana limitans interna bei Makulalöchern. Ophthalmologe 1997; 94: 545-551.
14. Gass JDM. Idiopathic macular hole; Its early stages and pathogenesis. Arch Ophthalmol 1988; 106: 629-639.
15. Faude F, Edel E, Dannhauer M, Petzel C, Meier P, Widemann P. Autologe Thrombozytenapplikation bei der Behandlung des idiopathischen Makulaforamens. Ophthalmologe 1997; 94: 877-881.
16. Minihan M, Goggin M, Cleary PE. Surgical management of macular holes: Results using gas tamonade alone, or in combination with autologous platelet concentrate, or transforming growth factor β2. Br J Ophthalmol 1997; 81: 1073-1079.
17. Margherio RR, Margherio AR, Williams GA, Chow DR, Banach MJ. Effect of perifoveal tissue dissection in the management of acute idiopathic full-thickness macular holes. Arch Ophthalmol 2000; 118: 495-498.
18. Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev 1993; 7: 52-62.
19. Herd CM, Page CP. Pulmonary immune cells in health and disease: Platelets. Eur Respir J 1994; 7: 1145-1160.
20. Beer HD, Longaker MT, Werner S. Reduced expression of PDGF-receptors during impaired wound healing. J Invest Dermatol 1997; 109: 132-138.
21. Hosgood G. Wound healing. The role of platelet-derived growth factor and transforming growth factor beta. Vet Surg 1993; 22: 490-495.
22. Ideka T, Puro DG. Regulation of retinal glial cell proliferation by anti proliferation molecules. Exp Eye Res 1995; 60: 435-444.
23. Sagar SM, Edwards RM, Sharp FR. Epidermal growth factor and transforming growth factor an induce c-fos gene expression in retinal Müller cells in vivo. J Neurosci Res 1991; 29: 549-559.
24. Uchiori Y, Puro DG. Mitogenic and chemotactic effects of platelet derived growth factor in human retinal glial cells. Invest Ophthalmol Vis Sci 1991; 32: 2689-2695.
25. Christmas NJ, Skolik SA, Howard MA, Saito Y, Barnstable CJ, Liggett PE. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology 1995; 102: 263-271.
26. Mester V, Kuhn F. Internal limiting membrane removal in the management of full-thickness macular holes. Am J Ophthalmol 2000; 129: 769-777.
27. Thompson JT, Sjaarda RN. Results of macular hole surgery in patients over 80 years of age. Retina 2000; 20: 433-438.
28. Smiddy WE, Feuer W, Cordahi G. Internal limiting membrane peeling in macular hole surgery. Ophthalmology 2001; 108: 1471-1478.
29. Park SS, Marcus DM, Duker JS, Pesavento RD, Topping TM, Frederick AR, D'Amico DJ. Posterior segment complications after vitrectomy for macular hole. Ophthalmology 1995; 102: 775-781.
30. Sjaarda RN, Glaser BM, Thompson JT, Murphy RP, Hanham A. Distribution of iatrogenic retinal breaks in macular hole surgery. Ophthalmology 1995; 102: 1387-1392.
31. Thompson JT, Sjaarda RN, Glaser BM, Murphy RP. Increased intraocular pressure after macular hole surgery. Am J Ophthalmol 1996; 121: 615-622.
32. Ezra E, Arden GB, Riordan-Eva P, Aylward GW, Gregor ZJ. Visual field loss following vitrectomy for stage 2 and 3 macular holes. Br J Ophthalmol 1996; 80: 519-525.
33. Hutton WL, Fuller DG, Snyder WB, Fellman RL, Swanson WH. Visual field defects after macular hole surgery; A new finding. Ophthalmology 1996; 103: 2152-2159.
34. Melberg NS, Thomas MA. Visual field loss after pars plana vitrectomy with air/fluid exchange. Am J Ophthalmol 1995; 120: 386-388.
35. Pendergast SD, McCuen BW. Visual field loss after macular hole surgery. Ophthalmology 1996; 103: 1069-1077.